Resistance and Viral Escape from Antivirals

Viruses replicate quickly and, especially RNA viruses, mutate often, so a drug that suppresses most of a viral population can select for the rare variants that survive it. Antiviral resistance is the outcome of this selection: genetic changes in the targeted viral protein that reduce a drug's binding or effect, allowing the virus to escape therapy.

Definition

Antiviral resistance is a heritable reduction in a virus's susceptibility to a drug, arising when mutations in the drug's target protein lower the drug's binding or activity and are then selected by ongoing drug exposure, allowing the resistant variant to replicate despite treatment.

Scope

This topic covers why and how viruses become resistant to antivirals — the role of viral mutation rates and population diversity, resistance-associated mutations in drug targets, the genetic barrier to resistance, and strategies such as combination therapy that constrain escape. It explains the biology of resistance, not how to manage a resistant infection in a patient.

Core questions

• Why are viruses, especially RNA viruses, prone to developing resistance?
• How do resistance-associated mutations reduce a drug's effect?
• What is the genetic barrier to resistance and why does it differ between drugs?
• How does combination therapy limit the emergence of resistance?
• What is the fitness cost of resistance mutations?

Key concepts

• Viral mutation rate and quasispecies diversity
• Resistance-associated mutations
• Selection under drug pressure
• Genetic barrier to resistance
• Combination (multi-drug) therapy
• Fitness cost of resistance
• Cross-resistance within a drug class
• Reassortment in segmented viruses

Mechanisms

Error-prone viral polymerases generate a diverse population (a quasispecies) in which variants with mutations in a drug's target may pre-exist. Drug exposure then selects these variants, which spread as the susceptible majority is suppressed. A drug's genetic barrier reflects how many mutations are needed to escape it; combination regimens raise that barrier because a virus must acquire resistance to several agents at once, the principle behind effective HIV therapy described by Arts and Hazuda (2012). De Clercq and Li (2016) note resistance as a recurring limit across antiviral classes, and resistance to neuraminidase inhibitors such as oseltamivir (tested by Nicholson et al., 2000) illustrates escape in influenza. In segmented viruses, reassortment offers an additional route to new genotypes that may carry resistance, as reviewed by McDonald et al. (2016). Resistance mutations often carry a fitness cost, so resistant variants may replicate less efficiently in the absence of the drug.

Clinical relevance

Resistance is a principal reason antiviral therapy can fail and a key rationale for combination regimens and resistance testing; understanding it is essential to interpreting why some treatments lose effect. This entry explains the biological basis of resistance and is not a guide to choosing or switching therapy, which requires clinical assessment.

History

Resistance emerged as a defining challenge in the HIV era, where single-drug therapy was rapidly undone by escape mutations until combination regimens raised the genetic barrier, a story told by Arts and Hazuda (2012). Similar dynamics in influenza and other viruses, catalogued alongside the approved-drug record by De Clercq and Li (2016), established resistance monitoring as a permanent feature of antiviral practice.

Key figures

• Erik De Clercq
• Daria Hazuda

Seminal works

• arts-hazuda-2012
• declercq-li-2016

Frequently asked questions

Why do viruses develop resistance to antiviral drugs?

Viruses replicate rapidly and mutate frequently, so rare variants with changes in the drug's target can survive treatment and then multiply as the drug suppresses the susceptible majority, leaving the resistant variant to predominate.

How does combination therapy slow resistance?

Using several drugs with different targets means the virus would have to acquire resistance mutations to all of them simultaneously, which is far less likely than developing resistance to a single drug.